A Pharmacokinetic Study of Lurasidone After Single Oral Administration in Healthy Subjects

NCT02174510 · clinicaltrials.gov ↗

PHASE1

Phase

COMPLETED

Status

37

Enrollment

INDUSTRY

Sponsor class

Conditions

Schizophrenia

Interventions

DRUG: 20mg lurasidone
DRUG: 40mg lurasidone
DRUG: 80mg lurasidone
DRUG: placebo

Sponsor

Sumitomo Pharma (Suzhou) Co., Ltd.

Collaborators

[object Object]